NCT03549299 - Allogeneic ABCB5-positive Limbal Stem Cells for Treatment of LSCD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 4, 2019

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions

Limbal Stem Cell Deficiency

Interventions

BIOLOGICAL

LSC2

Topical application of IMP on target eye

Trial Locations (5)

Universitäts-Klinikum Köln, Augenklinik, Cologne

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Augenklinik und Poliklinik, Mainz

Universitäts-Klinikum Heidelberg, Kopfklinik, Heidelberg

Massachusetts Eye and Ear Infirmary, Boston

Universitäts-Klinikum Jena, Augenklinik, Jena